Pregnancy Surveillance Program of Patients Exposed to Epidiolex/Epidyolex During Pregnancy
← catalyst calendarNCT06113237 · readout in 2,568 d
Sponsored by Jazz Pharmaceuticals (industry) · JAZZ — their whole pipeline →.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
50estimated
Sites
2
Countries
Germany, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-08-05 | actual | When the study began enrolling |
| Primary completion | 2033-08-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2033-08-31 | estimated | The whole study's end, after follow-up |
| First posted | 2023-11-02 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-24 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Maternal Complications
- Pregnancy Complication
- Birth Outcomes, Adverse
- Pregnancy
Intervention
- Drug: Epidiolex — also filed as Epidyolex, Cannabidiol
Primary outcome
what the primary-completion date above is the date OFRate of MCM
measured Up to 12 months post birth
Permalink · JAZZ's whole pipeline · Catalyst calendar · Every registered study · What changed